The study analyzed 20 clinical prediction models (CPMs) for rheumatoid arthritis (RA), all of which were deemed to have a high risk of bias, leading the researchers to urge against their use to guide decision-making without addressing their limitations.
There is a need for clinical prediction models (CPMs) that can successfully guide providers in using methotrexate for the treatment of rheumatoid arthritis, found a systemic review and meta-analysis.
The study analyzed 20 CPMs from 13 studies and 4 validation studies, all of which were deemed as having a high risk of bias (ROB), leading the researchers to urge against their use to guide decision making without addressing their limitations. The group largely attributed this to small sample sizes, lack of validation, insufficient handling of missing data, inconsistent reporting, and failure to account for discontinuation rates due to adverse events (AEs).
Their findings were published in Seminars in Arthritis & Rheumatism.
“Only one study predicted discontinuation due to AEs and model performance was poor. This may be due to the small outcome prevalence compared to predicting treatment response as defined through the DAS28 [health assessment questionnaire],” explained the researchers. “A relatively small outcome prevalence may result in low statistical power, leading to risk models making inaccurate predictions. As various outcome definitions are currently used, further input from patients and prescribers on which outcomes are clinically important may be valuable.”
In addition to AEs, outcomes analyzed in the study included state of disease activity and European Alliance of Associations for Rheumatology response criteria. According to the researchers, most models were able to predict state of disease activity, which they note may be due to treat-to-target recommendations that promote remission or low disease activity as quickly and safely as possible.
Just one model accounted for potential competing risks, an approach that could offer more realistic and clinically relevant predictions, the group wrote. Forty-rive percent of models were internally validated using recommended resampling techniques in the development dataset to correct for optimism.
Across the CPMs, the researchers found a lack of data reporting on certain patient characteristics, including comorbidities, which play an important role in methotrexate prescribing and response. Forty-rive percent of models included data on concomitant antirheumatic treatment.
There were 8 (40%) models that used multiple imputation to account for missing data, producing various plausible datasets and averaging results across each, which the researchers noted is considered a robust approach to account for missing data. The other models used complete case analysis, which is limited to patients with full baseline data available, resulting in smaller sample size for analysis.
“There are, however, some encouraging results identified by our review, as ROB was universally rated as low in the participants, predictors, and outcome domains, and the meta-analysis showed overall good performance of the 2 CPMs with multiple external validations,” described the researchers. “Therefore, once the methodological limitations outlined above are addressed, there is scope to develop an accurate CPM of methotrexate outcomes to guide treatment decisions in rheumatoid arthritis (upon undertaking appropriate impact assessment studies). However, even if patients at high risk of poor response of methotrexate were successfully identified, there is currently no clear indication that they will respond better to alternative therapies, such as biological disease-modifying antirheumatic drugs.”
Reference
Gehringer C, Martin G, Hyrich K, Verstappen S, Sergeant J. Clinical prediction models for methotrexate treatment outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. Published online July 31, 2022. doi:10.1016/j.semarthrit.2022.152076
Health Equity and Access Weekly Roundup: May 4, 2024
May 4th 2024This week, the Center on Health Equity and Access highlights a variety of gaps that exist in health care, spanning women's health, the rising rate of metabolic disease, and policy for LGBTQ+ and immigrant populations. The consensus among featured experts points to comprehensive care models.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
A new federal rule will enable thousands of immigrants in the Deferred Action for Childhood Arrivals (DACA) program to obtain health care through the Affordable Care Act; a forthcoming CMS rule is expected to lower home-based care wait times and raise caregiver wages; the HHS Office for Civil Rights has finalized 2 rules that strengthen the ACA’s health care discrimination ban.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Initiating BP Medication Linked to Higher Fall, Fracture Risks in Nursing Home Residents
May 2nd 2024Among over 60,000 nursing home residents who initiated antihypertensive medication, rates of excess fractures due to falls per 100 person-years were as high as 5 among certain patient groups, such as those with dementia and high blood pressure (BP).
Read More